Jaime Rosenberg

During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists debated whether newer targeted agents should be considered for first-line treatment in well-differentiated G3 neuroendocrine neoplasms (NENs), and if the standard of care—cytotoxic therapy—should still play a role in first-line treatment.

During a session at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington, panelists discussed the benefits of integrative oncology and nutrition for patients with neuroendocrine tumors.

An interim analysis of somatostatin analog lanreotide depot presented at the North American Neuroendocrine Tumor Society annual meeting, held October 4-6 in Seattle, Washington, found that the treatment was effective in disease control and most patients were satisfied with the treatment.

Two studies presented at the North American Neuroendocrine Tumor Society annual meeting October 4-6 in Seattle, Washington assessed different tools for determining quality of life among patients with neuroendocrine tumors (NETs).

Two studies presented at the 2018 Infectious Disease Week conference held in San Francisco, California, add to a pile of research demonstrating the positive impact of collaborative, multidisciplinary care in the HIV population, specifically on viral suppression.

While the integration of social determinants of health (SDOH) into electronic health records (EHRs) may be feasible, substantial barriers to adoption exist.

A new study has found that people living with HIV are at an increased risk of both first and second primary cancer incidence.

The majority of patients who suffer from migraine experience premonitory symptoms and are able to predict at least 1 attack, according to a new study.

Young men who have sex with men (MSM) who used the PrEPmate intervention were more likely to attend study visits and have higher rates of adherence to the prevention treatment.

A study has found that noninvasive vagus nerve stimulation can provide pain relief for up to 60 minutes after an acute attack.

The costs of pivotal trials ranged from $2.1 million to $346.8 million, with a central cluster of trials with estimated costs of $12.2 million to $33.1 million.

For patients with multiple sclerosis (MS) being treated with natalizumab, cognitive function improved from baseline to 1 year and improved significantly across all domains from baseline to 2 years.

Unstable housing among the HIV population is associated with decreased probability of viral suppression and adequate CD4 cell count. It also lowers the likelihood of mental health/counseling, visiting a healthcare provider, and engaging in continuity of care.

The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.

Noting a disconnect between evidence of benefit and uptake of exercise in patients with multiple sclerosis (MS), researchers offer behavioral science, specifically Social Cognitive Theory, as an approach to increasing participation.

As the country continues to grapple with best practices for combating the high prevalence of obesity, here are 5 things to know.

Senators Bill Cassidy, MD, R-Louisiana; Michael Bennet, D-Colorado; Chuck Grassley, R-Iowa; Tom Carper, D-Delaware; Todd Young, R-Indiana; and Clair McCaskill, D-Montana, have released the Protecting Patients from Surprise Medical Bills Act to protect patients from balanced billing for treatment and services from an out-of-network provider in an in-network facility.

A survey has revealed gaps in HIV providers’ knowledge of the Affordable Care Act. However, despite these gaps, the majority of surveyed providers expressed belief that Medicaid expansion would improve both HIV outcomes and general outcomes for patients with the disease.

With general consensus that those 70 years and older should not be routinely screened for prostate cancer, researchers argue that their study results identify an area for cutting low-value services to reduce healthcare spending.

Researchers determined that the current drug pipeline is unlikely to produce any highly effective vaccines for HIV, tuberculosis, or malaria, which could be important for controlling the spread of these diseases.

The survey of more than 340 women revealed an overwhelming belief that people with migraine are dismissed as exaggerating their symptoms and that employers don't understand the burden of migraine on their employees.

A National Comprehensive Cancer Network (NCCN) working group dedicated to analyzing current challenges under existing policy and treatment paradigms presented their findings and recommendations at an NCCN Policy Summit in Washington, DC.

As the term “value” has become a norm in healthcare, specifically in oncology, panelists at a National Comprehensive Cancer Network policy summit offered perspectives on where we are now in delivering high-quality cancer care under value-based payment models.

The lawsuit—filed by the American Hospital Association, America’s Essential Hospitals, the Association of American Medical Colleges, 340B Health, Genesis Healthcare System, Kearny County Hospital, and Rutland Regional Medical Center—is asking a federal court to order HHS to make the final rule effective within 30 days.

As levels of disability increased among patients with multiple sclerosis (MS), cost of illness increased and health-related quality of life decreased.

Two studies presented at the PAINWeek conference in Las Vegas, Nevada, took a look into the prevalence of acute medication use and overuse among migraineurs, as well as rates of medication discontinuation due to lack of efficacy or side effects.

While the rate remains unchanged from 2016, there was an observed shift from prescription opioids to other drugs and dangerous drug combinations.

With the expansion of Medicaid, eligible, low-income people living with HIV were transferred from the Ryan White Program to Medicaid, causing concern for interrupted access to care and treatment.

GammaCore Sapphire, the newest version of gammaCore—a noninvasive vagus nerve stimulator—is now available in the United States to treat patients with migraine and episodic cluster headache.

Since the formation of the nonprofit generic drug company in January, the company has grown to 7 health systems and has named its chief operating officer. Orignally announced as Project Rx, the company will now be named Civica Rx.